z-logo
Premium
Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C ( CHC ) infected patients evaluated with controlled attenuation parameter ( CAP )
Author(s) -
Cardoso A. C.,
Perez R. M.,
FigueiredoMendes C.,
Carvalho Leite N.,
MoraesCoelho H. S.,
VillelaNogueira C. A.
Publication year - 2018
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.12930
Subject(s) - steatosis , transient elastography , medicine , gastroenterology , fatty liver , liver steatosis , diabetes mellitus , hepatitis c , dyslipidemia , endocrinology , cirrhosis , obesity , liver fibrosis , disease
Summary A novel controlled attenuation parameter ( CAP ) using FibroScan ® has been developed for assessment of liver steatosis. The aim was to evaluate the frequency and associated factors for moderate/severe steatosis evaluated by CAP in CHC patients submitted to transient elastography ( TE ) by FibroScan ® . CHC patients underwent TE with CAP evaluation. The classification of steatosis was defined as: CAP < 222 dB /m  =  S0; CAP ≥ 222 dB /m and <233dB/m  =  S1; ≥233 dB /m < 290dB/m  =  S2 and >= 290 dB /m  =  S3. The prevalence of moderate/severe steatosis ( CAP ≥ S2) and the related independent factors were identified by a logistic regression analysis. A significance level of 5% was adopted. 1104 CHC patients, 85% genotype‐1 were included (mean age 55 ± 11 years; 46% male, mean BMI 25 ± 4 Kg/m 2 ). Systemic arterial hypertension and type 2 diabetes mellitus prevalences were 39% and 17%, respectively. Liver stiffness measurement ≥ 9.5 kP a was observed in 39% of patients and steatosis was identified in 50% (S1 = 7%, S2 = 28% and S3 = 15%). The variables independently associated with moderate/severe steatosis were: male gender ( OR =1.35; P  =   .037; 95% CI :1.01‐1.81); systemic arterial hypertension ( OR =1.57; P  =   .002; 95% CI :1.17‐2.10) and BMI ( OR =1.17; P  <   .01;95% CI :1.12‐1.22). In conclusion, when CAP was adopted as a tool to detect steatosis, genotype 1 CHC patients presented a high prevalence of moderate/advanced steatosis. In these patients, liver steatosis was associated mostly to metabolic factors (arterial hypertension and high BMI).

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here